acting P2 agonist salmeterol (100 rg) (n = 220) was compared with high dose inhaled steroid (1000 jtg BDP) (n = 206) in asthmatic outpatients in a double blind, parallel group study. Outcome measures consisted of a combined diary for peak expiratory flow (PEF) rate, symptoms, and problems, and an asthma-specific QOL questionnaire, the Living with Asthma Questionnaire. Results -The QOL diary correlated with the QOL questionnaire for both cross sectional and longitudinal assessments. Cross sectional correlations with PEF were higher for the QOL questionnaire than the QOL diary, but longitudinal correlations with PEF were higher for the diary than the questionnaire. Treatment with low dose steroidisalmeterol compared with high dose steroid produced better lung function, better QOL as measured by diary, and reduced night time wakenings, but treatment differences were not obtained with the QOL questionnaire nor for daytime symptoms. Diary assessed QOL was a better predictor of low PEF than diary assessed symptoms. Compliance with diary completion was good but there were floor or ceiling effects in the QOL diary records of about 25% of patients. Conclusions -Structured QOL diaries are valid instruments that appear to be more responsive to longitudinal change in clinical trials than a QOL questionnaire, but QOL questionnaires provide a more sensitive cross sectional measure of disease severity. Floor Four asthma-specific quality of life (QOL) questionnaires"1 and one life activity checklist5 have been published, all of which have been designed to measure QOL in clinical trials and all of which have acceptable validity. Each of these instruments requires patients to indicate how much they have been affected by asthma over a time span varying between two weeks and one year. However, asthma symptoms are also measured through the use of daily symptom diaries and, given the widespread use of diaries in asthma clinical trials, it would be feasible to measure some of the QOL deficits associated with asthma on a daily basis. Other research shows that the questionnaire assessment of life events introduces recall errors which increase with duration between event and recording,6 and in some circumstances diary assessments can be superior.7 This study examines the validity of an asthma-specific, structured QOL diary as an outcome measure in clinical trials.
Asthma can affect patients' QOL in many different ways. Thus, some patients may experience specific problems resulting from exacerbations of symptons during certain activities and be distressed either by the symptoms themselves or by the immediate loss or reduction of participation in activity that they cause. Other patients may then choose to avoid activities that they think are likely to cause exacerbations, and thus experience distress at missing out on the activity altogether. While questionnaires can measure all these different aspects of QOL deficit, diaries relate best to the first aspect -namely, specific problems that arise from exacerbations of symptoms pared with other deficits that are also included in QOL questionnaires.'0 In this study we examined the responsiveness of a structured QOL diary by comparing the ability of a diary and questionnaire to detect treatment differences. In addition, we examined the cross sectional and longitudinal correlations between the QOL diary, questionnaire, diary measured symptoms, and daily peak expiratory flow (PEF) to provide information about the validity of QOL diary methodology.
Methods

STUDY DESIGN
This multicentre, double blind, parallel group study compared two treatment regimens: beclomethasone dipropionate (BDP) 400 jtg daily plus salmeterol xinafoate 100 jig versus BDP 1000 gg daily. Patients were initially assessed over a two week baseline period during which they took BDP 400,g daily. On successful completion of the baseline, patients were randomly allocated to one of the two treatment groups over a six month period from which we report data for the first three months. PATIENT 
SELECTION
Patients aged between 18 and 75 were admitted into the baseline period if they were receiving 400 jg BDP via a metered dose inhaler or equivalent, and using a P2 agonist as required.
If, during the baseline study patients demonstrated a peak flow variation of at least 15% and recorded asthma symptoms for at least four of the last seven days, they were randomly allocated to one of the two treatment groups. Patients were excluded from the study if they were receiving maintenance oral corticosteroids or had received a short course of oral steroids in the six weeks before the start of the study or had received more than four short courses of oral steroids in the last year. Patients with a forced expiratory volume in one second (FEVI) of less than 50% predicted were also excluded, as were those who had changed asthma therapy in the six weeks before the start of the study. No specific time frame is specified; patients are asked to respond according to how they are at the time assessed.
QOL was measured by structured diary using a specially constructed diary card that elicited information about QOL as well as symptoms and PEF. The diary was constructed on the basis of the content of existing QOL questionnaires, and there were four categories of problem: (a) paid employment, assessments, studying; (b) domestic jobs, housework, gardening, shopping, DIY; (c) visiting friends, leisure, sports, enjoyment; and (d) missed appointments, not getting things done. Subjects responded in the evening to all four problems on each day of diary completion using the following six categories: not applicable, no problems, one minor problem, a few minor problems, several major problems, as bad as I could imagine. Symptoms were assessed in the evening but patients also recorded in the morning whether they had been woken the previous night and taken relief medication during the day. PEF was recorded morning and evening.
Because some patients complete diaries retrospectively,'2 they were instructed not to do so but to leave the space blank if they forgot on any day. The instructions were intended to legitimise forgetting and therefore to reduce the incentive to produce invalid data.
PROCEDURE
Patients completed the diary for the final seven days during a 14 day baseline period and for the first week of every month during the treatment period. The Living with Asthma Questionnaire was completed at the end of the baseline period and thereafter three monthly. We report data from the first three months of treatment of a longer trial.'3 DATA ANALYSIS
Scoring
The Living with Asthma Questionnaire (LWAQ) was scored using its two construct subscales.'4 Diary measures were scored as follows: problem incidence is the proportion of days when a problem was reported out of all days when either a problem or no problem was reported by the patient; problem severity is the average severity score on such days. Symptom incidence is the proportion of days out of all Table 8 shows the difference between mean PEF on days when patients did and did not report symptoms (no patients reported problems in the absence of symptoms) during the baseline period. Sixty two (for morning) and 61 (for evening) patients completed PEF on at least one day when they had no symptoms as well as at least one day when they had symptoms but no problems during the baseline period. For each of these patients mean PEF was calculated for the symptom-free days and for the symptom but no problem days. There was no significant difference in mean PEF between symptom and symptom-free days. Also shown in 9 . There were no significant differences between the two treatment groups for either of the two LWAQ subscales or symptom scores. Excluding the no change subjects for the purpose of the diary analysis (sample sizes are the same as for longitudinal correlational analysis above), salmeterol/BDP produced significantly better change for problem incidence (p = 0 02), problem severity (p<005), and night wakenings (p = 0-02). Table 9 shows the mean values for these patients, but if those patients exhibiting floor and ceiling effects are included in the analysis, the significance levels are slightly reduced (p = 0-02, p = 0 05, and p = <0 05, respectively), though still significant.
Discussion
Responsiveness to change is an important characteristic of a QOL instrument when it is used in a clinical trial.89 Although the Living with Asthma Questionnaire has been shown in two other studies4 15 to be able to detect treatment differences between salmeterol and placebo, we found in this study that it was unable to detect differences between salmeterol/BDP and high dose BDP. It may be that the questionnaire is able to detect improvement compared with no improvement but not able to distinguish different degrees of improvement. By contrast, the QOL structured diary was able to detect differences in level of improvement between salmeterol/BDP and high dose BDP. Although diaries are an established methodology for assessment of asthma symptoms and PEF,'6 the issue of patient compliance and validity remains. In this study patients were never required to complete a diary for more than seven days at a stretch. We found that patient compliance was good even though they were instructed to leave days blank if they forgot. Level There was good convergent validity between the diary and questionnaire and, in particular, the Functional limitation subscale of the questionnaire. The Functional limitation subscale (which in a previous study was found to be more sensitive to change than the Distress subscale'4) includes two kinds of items in several domains: those describing specific problems and those describing the avoidance of activities of which the diary assesses only the former. The high convergent validity (good cross sectional and longitudinal correlations) between Functional limitation and diary assessed problems is consistent with the diary assessing specific problems arising from the exacerbation of asthma.
The diary does not appear to be a particularly good measure of distress, and the additional information contained in the problems severity score in contrast to the problems incidence score did not add anything either to the correlations or responsiveness to change. It appears that rating the severity of a problem provides no more useful information than simply indicating whether a problem has occurred or not; however, this conclusion must be treated cautiously as most problems recorded in this study were minor rather than severe. Furthermore, as this was the first QOL diary to be used in a clinical trial it is yet to be determined whether other types of diary format lead to similar conclusions.
The mean PEF on days when patients reported only symptoms and days when they reported problems provides useful information about how diary reported problems differ from diary reported symptoms. We found that on some days patients reported no symptoms or problems, some days they reported symptoms and no problems, and some days they reported symptoms and problems (they never reported problems and no symptoms). The existence of symptoms alone was not associated with a lower PEF compared with symptom-free days, confirming the generally poor relationship between symptomatology and PEF.15 However, mean PEF was significantly lower on days when patients had problems compared with when they had symptoms and no problems. It would seem that patients report problems during the troughs of a PEF graph, whereas they report symptoms over a broader spectrum of values in a PEF graph. Diary-reported problems were more responsive to longitudinal change than diary-reported symptoms (but not night time symptoms). This is either because problems are a more responsive subjective measure than symptoms or because of treatment effects: it may be that salmeterol/BDP leads to a greater reduction in the more severe PEF troughs compared with the less severe PEF troughs than high dose BDP. In any case it would seem that problem diaries provide useful additional information compared with symptom diaries and can play a useful part in clinical trials.
In conclusion, patients seemed to find a structured QOL diary acceptable and completion rates were high under circumstances where patients never had to complete a diary for more than seven days in one stretch. Diary assessed QOL is a valid and responsive technique for measuring one component of QOL, but questionnaires provide a broader and more sensitive cross sectional measure. The major weakness with QOL diaries is that for some patients they exhibit floor and ceiling effects, and for these patients diaries are an invalid measure of change. Care must therefore be taken in clinical trials either to select out such patients or to develop diaries that are less prone to floor and ceiling effects.
QOL diaries measure patient perceived problems, and the patient's subjective awareness of problems is not the same as their awareness of symptoms. Diary recorded problems provide a better measure of the troughs in a PEF graph and we found them to be more sensitive to treatment changes than symptoms. Thus, diary reported QOL problems should be assessed in clinical trials where subjective reports of patients are an important outcome measure.
